Dr. Peter Attia, the longevity guru behind bestselling book 'Outlive' and a seven-year-old health optimization podcast, has stepped down as Chief Science Officer of David Protein, the New York-based nutrition startup announced Monday. The departure comes days after Attia's name surfaced in over 1,700 pages of documents related to Jeffrey Epstein, released Friday as part of a massive file dump. His other startup, Biograph, is quietly scrubbing his name from its website.
The longevity industry just hit a major speed bump. Dr. Peter Attia, one of the most recognizable voices in preventive health and human optimization, stepped down from his Chief Science Officer role at David Protein on Monday, according to a post on X by the company's founder. The timing isn't coincidental.
Days earlier, Attia's name appeared in more than 1,700 documents tied to convicted sex offender Jeffrey Epstein, released as part of a massive Friday file dump. The New York Times reported the contents included email correspondence that Attia later called "crude" in a lengthy response on X. While Attia denied criminal involvement and said he never visited Epstein's island or traveled on his plane, he acknowledged feeling "ashamed" of some exchanges and explained why he maintained contact even after Epstein's 2008 conviction.
For David Protein, a three-year-old startup that launched its flagship protein bar in September 2024, the loss of Attia removes a key credibility anchor. The Canadian-American physician wasn't just a science advisor - he was an early investor and executive team member at a company that bills its product as having 28 grams of protein, zero sugar, and 150 calories. Attia's bestselling book "Outlive: The Science and Art of Longevity" and his popular podcast made him the perfect spokesperson for a brand positioning itself at the intersection of nutrition science and performance optimization. He'd even recently been hired as a contributor to CBS.
The company had momentum. David Protein closed a $75 million Series A in May 2025, led by Greenoaks with participation from Valor Equity Partners. That's substantial capital for a consumer nutrition brand in an increasingly crowded market. Attia's scientific credibility and media presence likely played a role in securing that valuation and investor confidence.
But the fallout extends beyond protein bars. Biograph, the healthcare testing and longevity startup Attia co-founded with entrepreneur John Hering, is quietly distancing itself from its most famous founder. The company declined to comment when asked about Attia's ongoing role or why pages on its website that previously mentioned him now return "file not found" errors or simply omit his name entirely.
Biograph emerged from stealth exactly a year ago, as TechCrunch previously reported, backed by Vy Capital, Human Capital, Alpha Wave, and WndrCo, plus angel investors including Balaji Srinivasan. The company operates in the growing concierge medical services space, offering premium preventive health diagnostics to subscribers paying between $7,500 and $15,000 annually. Attia was prominently featured in the company's press release and website as a co-founder when it launched.
The silent treatment from Biograph speaks volumes. Rather than issue a statement clarifying Attia's status or defending his involvement, the company is scrubbing digital traces and stonewalling inquiries. That suggests internal discussions about liability, brand protection, and investor concerns are happening behind closed doors. For a startup selling $15,000-per-year health optimization services to wealthy clients, founder reputation isn't just important - it's the entire value proposition.
The situation highlights a growing risk for startups built around personality-driven founders, especially in the wellness and longevity space where trust and credibility are currency. Attia spent years building authority through his podcast, book, and media appearances. That platform made him valuable to investors and co-founders. But it also meant his personal brand became inseparable from the companies he touched.
Investors in both David Protein and Biograph now face uncomfortable questions about due diligence and founder risk. Did they know about Attia's Epstein connections? Should they have? And what happens to valuations when the scientific credibility anchoring your brand suddenly becomes a liability?
For David Protein, the path forward likely involves repositioning around founder Peter Rahal and doubling down on product performance metrics rather than celebrity endorsements. The company's Series A gives it runway to weather the storm, but losing your CSO and early investor in one weekend is never part of the plan.
Biograph faces trickier terrain. As a co-founder, Attia's equity stake and legal role can't be erased with a website update. The company's silence suggests ongoing negotiations - possibly about transitioning responsibilities, restructuring equity, or managing investor relations. With concierge medicine clients paying five figures annually, any whiff of scandal or instability could trigger subscriber churn.
The longevity industry has exploded in recent years, fueled by wealthy individuals willing to pay premium prices for cutting-edge preventive care and life extension strategies. Attia was one of its most visible champions. His fall from grace won't kill the industry, but it does serve as a reminder that in an sector built on optimizing human performance, human frailty remains the biggest variable.
The Peter Attia situation is a case study in founder risk management - or the lack thereof. Within 72 hours of document release, one of longevity's biggest names lost his CSO position and saw his co-founded startup begin erasing his digital footprint. For David Protein and Biograph, the challenge now is rebuilding credibility without the celebrity scientist who helped define their brands. For investors, it's a reminder that personality-driven startups carry unique vulnerabilities that no amount of due diligence can fully insulate against. The longevity industry will continue its growth trajectory, but this episode will likely make VCs more cautious about building companies too dependent on a single charismatic founder's personal brand.
